BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25616285)

  • 21. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
    Wang H; Chi ZF; Li S; Wang XL; Hao LC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
    Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
    Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate.
    Cwiklinska M; Czogala M; Kwiecinska K; Madetko-Talowska A; Szafarz M; Pawinska K; Wieczorek A; Klekawka T; Rej M; Stepien K; Halubiec P; Lazarczyk A; Miklusiak K; Bik-Multanowski M; Balwierz W; Skoczen S
    Front Pediatr; 2020; 8():307. PubMed ID: 32612964
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.
    Lingg RM; Hempel G; Rots MG; Van Zantwijk CH; Boos J; Kaspers GJ
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):322-7. PubMed ID: 15868145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
    Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
    PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children.
    Dufourg MN; Landman-Parker J; Auclerc MF; Schmitt C; Perel Y; Michel G; Levy P; Couillault G; Gandemer V; Tabone MD; Demeocq F; Vannier JP; Leblanc T; Leverger G; Baruchel A
    Leukemia; 2007 Feb; 21(2):238-47. PubMed ID: 17170721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
    Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
    Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymidylate synthase enhancer region polymorphism not related to susceptibility to acute lymphoblastic leukemia in the Kashmir population.
    Nazki FH; Masood A; Banday MA; Bhat A; Ganai BA
    Genet Mol Res; 2012 Apr; 11(2):906-17. PubMed ID: 22576918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.
    den Hoed MA; Lopez-Lopez E; te Winkel ML; Tissing W; de Rooij JD; Gutierrez-Camino A; Garcia-Orad A; den Boer E; Pieters R; Pluijm SM; de Jonge R; van den Heuvel-Eibrink MM
    Pharmacogenomics J; 2015 Jun; 15(3):248-54. PubMed ID: 25348617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
    Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
    Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity.
    Borman P; Taşbaş Ö; Karabulut H; Tukun A; Yorgancıoğlu R
    Rev Bras Reumatol; 2015; 55(6):485-92. PubMed ID: 25687398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
    Refsum H; Wesenberg F; Ueland PM
    Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
    Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
    J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.